Autoantibodies in pre-clinical autoimmune disease

Clinica Chimica Acta

Volumn 437, Issue , 2014, Pages 14-18

  Hu, Zhi De ^a   Deng, An Mei ^b  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Autoantibodies; Autoimmune disease; Pre clinical phase

Indexed keywords

AUTOANTIBODY;

ANTIBODY DETECTION; AUTOIMMUNE DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; EARLY DIAGNOSIS; EXPERIMENTAL DESIGN; HIGH RISK PATIENT; HUMAN; INFLAMMATORY BOWEL DISEASE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BLOOD; IMMUNOLOGY; SJOGREN'S SYNDROME;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; SJOGREN'S SYNDROME;

EID: 84904394710     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.06.015     Document Type: Review

References (66)

1. Deane K.D. Preclinical rheumatoid arthritis (autoantibodies): an updated review. Curr Rheumatol Rep 2014, 16:419.
2. Bizzaro N. Autoantibodies as predictors of disease: the clinical and experimental evidence. Autoimmun Rev 2007, 6:325-333.
3. Bizzaro N. The predictive significance of autoantibodies in organ-specific autoimmune diseases. Clin Rev Allergy Immunol 2008, 34:326-331.
4. Ingegnoli F., Castelli R., Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers 2013, 35:727-734.
5. Diagnostic criteria for rheumatoid arthritis: 1958 revision by a Committee of the American Rheumatism Association. Ann Rheum Dis 1959, 18:49-51. [French transl 51-42; Spanish transl 52-43].
6. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
7. Aletaha D., Neogi T., Silman A.J., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
8. Halldorsdottir H.D., Jonsson T., Thorsteinsson J., Valdimarsson H. A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor. Ann Rheum Dis 2000, 59:149-151.
9. Majka D.S., Deane K.D., Parrish L.A., et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 2008, 67:801-807.
10. Kokkonen H., Mullazehi M., Berglin E., et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 2011, 13:R13.
11. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749.
12. Bos W.H., Nielen M.M., Dijkmans B.A., van Schaardenburg D. Duration of pre-rheumatoid arthritis anti-cyclic citrullinated peptide positivity is positively associated with age at seroconversion. Ann Rheum Dis 2008, 67:1642.
13. Nielen M.M., van Schaardenburg D., Reesink H.W., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386.
14. Kolfenbach J.R., Deane K.D., Derber L.A., et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum 2010, 62:2633-2639.
15. Turesson C., Bergstrom U., Jacobsson L.T., Truedsson L., Berglund G., Saxne T. Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritis. Ann Rheum Dis 2011, 70:520-522.
16. Nielen M.M., van Schaardenburg D., Reesink H.W., et al. Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis 2006, 65:535-537.
17. Jonsson T., Thorsteinsson J., Valdimarsson H. Elevation of only one rheumatoid factor isotype is not associated with increased prevalence of rheumatoid arthritis-a population based study. Scand J Rheumatol 2000, 29:190-191.
18. Chibnik L.B., Mandl L.A., Costenbader K.H., Schur P.H., Karlson E.W. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol 2009, 36:706-711.
19. Berglin E., Padyukov L., Sundin U., et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004, 6:R303-R308.
20. van de Stadt L.A., de Koning M.H., van de Stadt R.J., et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011, 63:3226-3233.
21. Sokolove J., Bromberg R., Deane K.D., et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 2012, 7:e35296.
22. Shi J., van de Stadt L.A., Levarht E.W., et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum 2013, 65:911-915.
23. van der Linden M.P., van der Woude D., Ioan-Facsinay A., et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009, 60:2232-2241.
24. Kudo-Tanaka E., Ohshima S., Ishii M., et al. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol 2007, 26:1627-1633.
25. van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J., et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004, 50:709-715.
26. Wevers-de Boer K.V., Heimans L., Huizinga T.W., Allaart C.F. Drug therapy in undifferentiated arthritis: a systematic literature review. Ann Rheum Dis 2013, 72:1436-1444.
27. Bos W.H., Wolbink G.J., Boers M., et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2010, 69:490-494.
28. Jorgensen K.T., Wiik A., Pedersen M., et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 2008, 67:860-866.
29. del Puente A., Knowler W.C., Pettitt D.J., Bennett P.H. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum 1988, 31:1239-1244.
30. Nielsen S.F., Bojesen S.E., Schnohr P., Nordestgaard B.G. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 2012, 345:e5244.
31. Waltuck J., Buyon J.P. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994, 120:544-551.
32. Aho K., Koskela P., Makitalo R., Heliovaara M., Palosuo T. Antinuclear antibodies heralding the onset of systemic lupus erythematosus. J Rheumatol 1992, 19:1377-1379.
33. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
34. Arbuckle M.R., James J.A., Kohlhase K.F., Rubertone M.V., Dennis G.J., Harley J.B. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001, 54:211-219.
35. Heinlen L.D., McClain M.T., Merrill J., et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007, 56:2344-2351.
36. McClain M.T., Arbuckle M.R., Heinlen L.D., et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004, 50:1226-1232.
37. Heinlen L.D., McClain M.T., Ritterhouse L.L., et al. 60kD Ro and nRNP A frequently initiate human lupus autoimmunity. PLoS One 2010, 5:e9599.
38. Eriksson C., Kokkonen H., Johansson M., Hallmans G., Wadell G., Rantapaa-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011, 13:R30.
39. McCune A.B., Weston W.L., Lee L.A. Maternal and fetal outcome in neonatal lupus erythematosus. Ann Intern Med 1987, 106:518-523.
40. Jonsson R., Theander E., Sjöström B., Brokstad K., Henriksson G. Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA 2013, 310:1854-1855.
41. Prince M.I., Chetwynd A., Craig W.L., Metcalf J.V., James O.F. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004, 53:865-870.
42. Mitchison H.C., Bassendine M.F., Hendrick A., et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?. Hepatology 1986, 6:1279-1284.
43. Metcalf J.V., Mitchison H.C., Palmer J.M., Jones D.E., Bassendine M.F., James O.F. Natural history of early primary biliary cirrhosis. Lancet 1996, 348:1399-1402.
44. Kisand K.E., Metskula K., Kisand K.V., Kivik T., Gershwin M.E., Uibo R. The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples. J Gastroenterol 2001, 36:248-254.
45. Lindor K.D., Gershwin M.E., Poupon R., Kaplan M., Bergasa N.V., Heathcote E.J. Primary biliary cirrhosis. Hepatology 2009, 50:291-308.
46. Israeli E., Grotto I., Gilburd B., et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005, 54:1232-1236.
47. van Schaik F.D., Oldenburg B., Hart A.R., et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut 2013, 62:683-688.
48. Berger T., Rubner P., Schautzer F., et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003, 349:139-145.
49. Kuhle J., Pohl C., Mehling M., et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007, 356:371-378.
50. Pelayo R., Tintore M., Montalban X., et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 2007, 356:426-428.
51. Chan A., Decard B.F., Franke C., et al. Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis. Mult Scler 2010, 16:1189-1192.
52. Lim E.T., Berger T., Reindl M., et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005, 11:492-494.
53. Pittock S.J., Reindl M., Achenbach S., et al. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler 2007, 13:7-16.
54. Berger T., Reindl M. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007, 356:1888-1889. [author reply 1888-1889].
55. Tomassini V., De Giglio L., Reindl M., et al. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 2007, 13:1086-1094.
56. Kuhle J., Lindberg R.L., Regeniter A., et al. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 2007, 254:160-168.
57. Rauer S., Euler B., Reindl M., Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 2006, 77:739-742.
58. Greeve I., Sellner J., Lauterburg T., et al. Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort. Acta Neurol Scand 2007, 116:207-210.
59. Sturgeon C.M., Viljoen A. Analytical error and interference in immunoassay: minimizing risk. Ann Clin Biochem 2011, 48:418-432.
60. Palazzi C., Buskila D., D'Angelo S., D'Amico E., Olivieri I. Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev 2012, 11:659-663.
61. Horn P.S., Pesce A.J. Reference intervals: an update. Clin Chim Acta 2003, 334:5-23.
62. Feitsma A.L., Toes R.E., Begovich A.B., et al. Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients. Rheumatology (Oxford) 2007, 46:1092-1095.
63. Perricone C., Agmon-Levin N., Ceccarelli F., Valesini G., Anaya J.M., Shoenfeld Y. Genetics and autoantibodies. Immunol Res 2013, 56:206-219.
64. van de Stadt L.A., Witte B.I., Bos W.H., van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis 2013, 72:1920-1926.
65. van der Helm-van Mil A.H., le Cessie S., van Dongen H., Breedveld F.C., Toes R.E., Huizinga T.W. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007, 56:433-440.
66. Shmerling R.H. Autoantibodies in systemic lupus erythematosus-there before you know it. N Engl J Med 2003, 349:1499-1500.